{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=20&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 10545,
    "total_pages": 1055,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=21&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=19&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T05:39:27.292Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mesothelioma",
        "Pleural Mesothelioma",
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab and Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2021-02-18",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • Miami, Florida • Tampa, Florida + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04334759"
    },
    {
      "nct_id": "NCT01195662",
      "title": "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 2245,
      "start_date": "2010-10",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2016-12-29",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 155,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01195662"
    },
    {
      "nct_id": "NCT00004583",
      "title": "A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Lopinavir/Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "1999-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-02-20",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 42,
      "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004583"
    },
    {
      "nct_id": "NCT02925494",
      "title": "An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Heavy Menstrual Bleeding"
      ],
      "interventions": [
        {
          "name": "Estradiol/Norethindrone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Elagolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 433,
      "start_date": "2016-09-14",
      "completion_date": "2019-03-22",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925494"
    },
    {
      "nct_id": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Malignant Neoplasm in the Lymph Nodes",
        "Metastatic Malignant Neoplasm in the Soft Tissue",
        "Metastatic Malignant Neoplasm in the Viscera",
        "Rhabdoid Tumor of the Kidney",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1175,
      "start_date": "2019-06-07",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 858,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793166"
    },
    {
      "nct_id": "NCT02974322",
      "title": "A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "GED-0301",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-01",
      "completion_date": "2018-12-24",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 136,
      "location_summary": "Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974322"
    },
    {
      "nct_id": "NCT00250679",
      "title": "Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Bronchitis",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "Arformoterol tartrate inhalation solution",
          "type": "DRUG"
        },
        {
          "name": "Arformoterol 25 ųg BID",
          "type": "DRUG"
        },
        {
          "name": "Formoterol 12 ųg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 443,
      "start_date": "2005-10",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-04",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00250679"
    },
    {
      "nct_id": "NCT03894046",
      "title": "Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex",
        "Hospital-acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Colistin Resistant ABC"
      ],
      "interventions": [
        {
          "name": "Sulbactam",
          "type": "DRUG"
        },
        {
          "name": "Durlobactam",
          "type": "DRUG"
        },
        {
          "name": "Colistin",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin 500 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Entasis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2019-09-05",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894046"
    },
    {
      "nct_id": "NCT04368988",
      "title": "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (NSS), Placebo - Phase 1",
          "type": "OTHER"
        },
        {
          "name": "Normal saline solution (NSS), Placebo - Phase 2",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (NSS), Placebo, Day 21 - Phase 1",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 1419,
      "start_date": "2020-05-25",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 8,
      "location_summary": "Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more",
      "locations": [
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368988"
    },
    {
      "nct_id": "NCT03425188",
      "title": "Post Approval Study of the remedē System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Central Sleep Apnea"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Respicardia, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2018-06-28",
      "completion_date": "2020-08-04",
      "has_results": true,
      "last_update_posted_date": "2021-04-22",
      "last_synced_at": "2026-11-01T05:39:27.292Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Downers Grove, Illinois + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Downers Grove",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03425188"
    }
  ]
}